IMPORTATION OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE

QUESTIONS AND ANSWERS

VERSION 4.1

Document history:

| Date of submission of draft to the Pharmaceutical Committee: ¹ |  |
| Date of publication: | See above |
| Date of entry into force: | N/A |
| Supersedes: | Version 4.0 of April 2013 |
| Changes compared to superseded version 4.0: | Q&A 11b (on "atypical active substances") has been removed (additional discussions with Member States are needed). |

Important notice: The views expressed in this questions and answers document are not legally binding. Ultimately, only the European Court of Justice can give an authoritative interpretation of Union law.

This document sets out frequently-asked 'questions and answers' regarding the new rules for the importation of active substances for medicinal products for human use.

These rules are contained in Articles 46b and 111b of Directive 2001/83/EC.

The 'written confirmation' is addressed in Article 46b(2)(b) of Directive 2001/83/EC.

1. **Question:** When do the new rules for the written confirmation apply?

Answer: They apply as of 2 July 2013. Any active substance imported into the EU from that date is subject to the rules on the written confirmation.

2. **Question:** Do the rules on the written confirmation also apply to active substances for veterinary medicinal products?

Answer: No. The rules apply only to active substances for medicinal products for human use.

2A. **Question:** Do the rules on the written confirmation also apply to blood plasma?

Answer: No. However, processed derivatives of plasma having a pharmacological, immunological or metabolic action are considered as active substance and written confirmation is thus required.

3. **Question:** Do the rules on the written confirmation apply to active substances for medicinal products intended for research and development trials?

Answer: No. Active substances used for investigational medicinal products or for medicinal products intended for research and development trials are excluded from the rules.

4. **Question:** Do the rules on the written confirmation apply to active substances which are brought into the EU without being imported ('introduced' active substances)? An example is the introduction of an active substance which is subsequently exported.

Answer: No. The rules on the written confirmation only apply to the import of active substances for medicinal products for human use.

5. **Question:** What if, at the time of export of an active substance to the EU, it is not known whether the active substance is used in a medicinal product for human use or not?

Answer: If the consignment is not accompanied by a written confirmation, the active substance cannot be used in a medicinal product for human use.

6. **Question:** Is the written confirmation expected to confirm compliance with EU-rules?

Answer: No. The written confirmation has to confirm compliance with GMP rules 'equivalent' to the rules applied in the EU.
7. **QUESTION:** IN MY NON-EU COUNTRY, THE APPLICABLE STANDARDS FOR MANUFACTURING OF ACTIVE SUBSTANCES ARE THE GOOD MANUFACTURING PRACTICES FOR ACTIVE SUBSTANCES OF THE WORLD HEALTH ORGANISATION (WHO) – FORTY-FOURTH TECHNICAL REPORT, NO. 957, 2010, ANNEX 2. ARE THESE STANDARDS EQUIVALENT TO THOSE IN THE EU, AS REQUIRED ACCORDING TO EU LEGISLATION?

Answer: Yes.

8. **QUESTION:** IN MY NON-EU COUNTRY, THE APPLICABLE STANDARDS ARE ICH Q7. ARE THESE STANDARDS EQUIVALENT TO THOSE IN THE EU, AS REQUIRED ACCORDING TO EU LEGISLATION?

Answer: Yes.

9. **QUESTION:** DOES THE WRITTEN CONFIRMATION HAVE TO BE ISSUED BY A CENTRAL, REGIONAL OR LOCAL AUTHORITY?

Answer: Each non-EU country decides autonomously which body within that country issues the written confirmation. That non-EU country may decide to issue the written confirmation at central, regional or local level.

10. **QUESTION:** DO THE RULES APPLY ALSO TO ACTIVE SUBSTANCES CONTAINED IN AN IMPORTED FINISHED MEDICINAL PRODUCT?

Answer: No. Regarding finished medicinal products, the rules for importation of finished medicinal products (importation authorisation and batch release by a qualified person, see Articles 40(3) and 51 of Directive 2001/83/EC) apply. These rules remain unchanged.

10A: **QUESTION:** IS WRITTEN CONFIRMATION ALSO REQUIRED FOR STARTING MATERIAL USED FOR THE PRODUCTION OF AN ACTIVE SUBSTANCE, FOR EXAMPLE BY WAY OF PURIFICATION OR FURTHER SYNTHESIS?

Answer: No. Such starting material does not fulfil the definition of Article 1(3a) of Directive 2001/83/EC.

11. **QUESTION:** IS THE WRITTEN CONFIRMATION ALSO REQUIRED FOR IMPORTED ACTIVE SUBSTANCES WHICH HAVE ALREADY BEEN MIXED WITH EXCIPIENTS, WITHOUT YET BEING THE FINISHED MEDICINAL PRODUCT?

Answer: No. Such partial manufacturing of the finished product is not included in the rules on the written confirmation.

11A. **QUESTION:** IS THE WRITTEN CONFIRMATION ALSO REQUIRED WHERE THE FINISHED DOSAGE FORM MANUFACTURED IN THE EU IS DESTINED FOR EXPORTATION ONLY?

Answer: Yes.
12. **Question: Who checks that the imported active substance is accompanied by the written confirmation?**

**Answer:** This should be checked by the receiving manufacturer of the finished medicinal product. It may also be checked by the importer of the active substance upon its importation.

The verification whether such checks take place depends on the transposing law of the Member State where the active substance is imported. It may be verified

- by the relevant authority upon importation; and/or

- in the context of an inspection of the importer of the active substance, and/or

- in the context of an inspection of the manufacturer of the medicinal product that uses the imported active substance.

13. **Question: How can I check if the written confirmation is authentic?**

**Answer:** You should contact the manufacturer of the active substance or the issuing authority in the non-EU country.

14. **Question: Is the written confirmation sent to an EU regulatory agency?**

**Answer:** No. The written confirmation accompanies the imported active substance.

15. **Question: Does the written confirmation have to be submitted with a request for authorisation of a marketing authorisation of a medicinal product?**

**Answer:** No.

16. **Question: Is the written confirmation to be issued for each batch/consignment?**

**Answer:** No. The written confirmation is issued per manufacturing plant and the active substance(s) manufactured on this site.

17. **Question: Does each imported consignment have to be accompanied by the written confirmation?**

**Answer:** Yes.

18. **Question: Is it acceptable that the written confirmation accompanying the imported consignment of the active substance is a copy?**

**Answer:** Yes, provided that the original written confirmation is still valid.
18A: **Question:** Regarding the written confirmation of 'equivalent' standards of good manufacturing practice, can the issuing authority of the non-EU country base itself on inspection results from EU authorities or other authorities applying equivalent standards for good manufacturing practice, such as US FDA?

Answer: Yes. In this case, the written confirmation should indicate which authority has inspected the site.

18B: **Question:** Regarding the written confirmation of 'equivalent' standards of good manufacturing practice, can the issuing authority of the non-EU country base itself on inspections conducted in the past?

Answer: Yes. It is not necessary to conduct an inspection specifically for the purpose of issuing the 'written confirmation'.

19. **Question:** What is the validity period of the written confirmation?

Answer: The validity of the written confirmation is established by the issuing authority of the non-EU country.

19A. The written confirmation refers to 'unannounced inspections'. Does this mean that an unannounced inspection has to have been conducted?

Answer: No. Rather, the system of supervision as a whole (including different types of inspections, such as unannounced inspections) has to ensure a protection of public health at least equivalent to that in the EU.

20. **Question:** If active substances are manufactured in a non-EU country 'A', but imported in the EU via the non-EU country 'B', who has to issue the written confirmation?

Answer: The written confirmation accompanying the imported active substance has to be issued by the non-EU country where the active substance is manufactured (i.e. non-EU country 'A').

21. **Question:** The template for the written confirmation refers to a 'confirmation number'. Does this number have to be a sequential number per country?

Answer: No. This number would be attributed by the issuing authority of the non-EU country.
22. **Question:** The template for the written confirmation refers to a 'responsible person' in the issuing authority. Does this responsible person have to have a specific qualification?

Answer: No. The 'responsible person' in this context is the person responsible within the administration for issuing the written confirmation.

23. **Question:** According to the template for the written confirmation, information of findings relating to non-compliance are supplied to the EU. To whom this information should be sent to?

Answer: The information should be sent to the European Medicines Agency (qdefect@ema.europa.eu).

24. **Question:** Is the written confirmation also required where there is a 'mutual recognition agreement' between a non-EU country and the EU?

Answer: Yes. The process of a written confirmation is independent of the existence of 'mutual recognition agreements'.

25. **Question:** If a manufacturing plant is located in a non-EU country 'A', can the written confirmation be issued by an authority in another non-EU country (non-EU country 'B')?

Answer: No.

26. **Question:** Are there exceptions from the requirement of a written confirmation?

Answer: The Commission publishes a list of countries which, following their request, have been assessed and are considered as having equivalent rules for good manufacturing practices to those in the EU. Active substances manufactured in these countries do not require a written confirmation.

See also Questions n° 27 and 28.

27. **Question:** Where can I find the list of non-EU countries to which the requirement of a written confirmation does not apply?


28. **Question:** How many non-EU countries have so far requested to be listed?

Answer: A list of non-EU countries which have so far requested to be listed is available here: [http://ec.europa.eu/health/human-use/quality/index_en.htm](http://ec.europa.eu/health/human-use/quality/index_en.htm).
29. **Question: When is the list going to be published by the Commission?**

Answer: The Commission is going to publish an additional non-EU country on the list once its equivalence assessment has been finalised. The equivalence-assessment takes several months from the request from the non-EU country.

29A. **Question: How does a non-EU country request to be listed?**

Answer: The request is made by way of a letter to the responsible Director-General, Ms Paola Testori Coggi (Paola.Testori@ec.europa.eu, office B232 07/058, BE-1049 Brussels, Belgium). It should contain the relevant information for conducting the 'equivalence assessment'. A list of that information is published here: http://ec.europa.eu/health/human-use/quality/index_en.htm#ias.

In the alternative, the request is made by way of a short letter to the responsible Director-General, and the relevant information is sent as follow-up information to the responsible service within the Commission (sanco-pharmaceuticals-d6@ec.europa.eu).

29B. **Question: By when should the request to be listed be made?**

Answer: The request should be listed as soon as possible. It is strongly recommended to make the request before end-2012.

If the request is made late, it may be impossible to conclude the equivalence-assessment before the date of application of the rules in July 2013.

30. **Question: Do I need a written confirmation, even though my manufacturing site has recently been inspected by the European Directorate for the Quality of Medicines (EDQM) of the Council of Europe?**

Answer: Yes. The process of a written confirmation is independent of such inspection activities. See also Question n° 31.

31. **Question: Do I need a written confirmation, even though my manufacturing site has recently been inspected by an EU Member State?**

Answer: Yes. The process of a written confirmation is independent of such inspection activities. However, exceptionally and where necessary to ensure the availability of medicinal products, following inspections by a EU Member State, a Member State may decide to waive the need for a written confirmation for a period not exceeding the validity of the GMP certificate ('waiver').

32. **Question: I would like to be inspected by an EU Member State. Where do I 'apply' for such an inspection?**

Answer: You should address through
• any registered importer of the active substance;
• any holder of a manufacturing authorisation that uses the active substance;
• any holder of a marketing authorisation that lists the active substance
  manufacturer

to the national competent authority of the EU Member State where they are established.

***